MicroRNA-155 is a novel prognosticator in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
Objective:Acute myeloid leukemia(AML)needs fine risk stratification to get an optimal outcome of patients.MiRNAs have important biological functions and play important roles in pathogenesis and prognosis in AML.Whether the overexpression of miR-155 also predicts poor outcome of AML patients undergoing allogeneic hematopoietic stem cell transplantation(allo-HSCT)is still unclear.Methods:We screened the The Cancer Genome Atlas(TCGA)database for AML patients with miRNA expression information and had underwent allo-HSCT.The expression levels of miRNA,clinical and molecular information of these AML patients were publicly accessible from the TCGA database.The patients were divided into two groups based on the median expression of miR-155.The clinical and molecular characteristics were summarized with descriptive statistics.The Mann-Whitney U test,the chi-square test,univariate and multivariate analyseswere used.Results:Except for BM blasts,FLT3-ITD mutations and TP53 mutations,there were no significant differences in clinical and genetic data between the two groups.By univariate analyses we identified high expression of miR-155 was unfavorable for OS,mutations in PHF6、RUNX1、TP53and MLL-PTD negatively affected OS.Further multivariate analyses indicated that high expression of miR-155 was an independent factor for poor OS.Conclusion:High miR-155 expression also correlates with poor prognosis in AML patients undergoing allo-HSCT,like it is regarded as a biomarker for poor prognosis in AML.
NETL
NSTL
万方数据
